The combination of urine DD3PCA3 mRNA and PSA mRNA as molecular markers of prostate cancer

Biomarkers

Volumn 14, Issue 4, 2009, Pages 235-243

  Mearini, Ettore ^a   Antognelli, Cinzia ^a   Del Buono, Chiara ^a   Cochetti, Giovanni ^a   Giannantoni, Antonella ^a   Nardelli, Emanuela ^a   Talesa, Vincenzo N ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Benign prostatic hyperplasia; DD3 mRNA; Molecular markers; Prostate cancer; PSA mRNA; Urine sediments

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN DD3 PCA3; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; PROSTATE CANCER ANTIGEN 3, HUMAN; TESTOSTERONE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; GENETICS; MIDDLE AGED; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINE;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 68549091013     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902807306     Document Type: Article

References (29)

1. Anderson NL, Anderson NG. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteom J 1:845-867
2. Bussemakers MJ, Van Bokhoven A, Gerald W, Verhaegh GW, Smit FP, Karthaus HFM, Schalken JA, Debruyne FMJ, Ru N, Isaacs WB. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975-5979
3. Cleutjens KB, Van Eekelen CC, Van der Korput HA, Brinkmann AO, Trapman J. (1996). Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388
4. De Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. (2002). DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62:2695-2698
5. Frydeberg M, Stricker PD, Kaye KW. (1997). Prostate cancer diagnosis and management. Lancet 349:1681-1687
6. Gandini O, Luci L, Stigliano A, Lucera R, Di Silverio F, Toscano V, Cardillo MR. (2003). Is DD3 a new prostate-specific gene? Anticancer Res 23:305-308
7. Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. (2006). APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52:1089-1095
8. Harden SV, Guo Z, Epstein JI, Sidransky D. (2003). Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 169:1138-1142
9. Hessels D, Klein Gunnewiek JMT, Van Oort I, Karthaus HFM, Van Leenders GJL, Van Balken B, Kiemeney LA, Witjes JA, Schalken JA. (2003). DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8-16.
10. Kattan MW. (2003). Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95:634-635
11. Khimani AH, Mhashilkar AM, Mikulskis A, O'Malley M, Liao J, Golenko EE, Mayer P, Chada S, Killian JB, Lott ST. (2005). Housekeeping genes in cancer: normalization of array data. Biotechniques 38:739-745
12. Lin MF, Lee MS, Garcia-Arenas R, Lin FF. (2000). Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells. Cell Biol Int 24:681-689
13. Marangoni K, Neves A, Cardoso A, Santos W, Faria P, Goulart L. (2006). The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prevent 30:7-13.
14. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. (2007). PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532-535
15. Migliaccio A, Pagano M, Auricchio F. (1993). Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 8:183-219.
16. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. (1992). Hormonal regulation of prostate- specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line LNCaP. Prostate 21:63-73.
17. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. (2007). Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041
18. Perkin-Elmer Corporation. (1997). ABI Prism 7700 Sequence Detection System. User Bulletin No 2. P/N 4303859. Rev A Stock No. 777802-778001
19. Ruckle HC, Oesterling JE. (1993). Prostate-specific antigen and androgen therapy. World J Urol 11:227-232
20. Schalken JA, Hessels D, Verhaegh G. (2003). New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62(5 Suppl. 1):34-43.
21. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051
22. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. (2008). PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology [Epub ahead of print].
23. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, Groskopf J, Vessella RL. (2008). A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389:1-6.
24. Sofikerim M, Eskicorapci S, Oruc O, Ozen H. (2007). Hormonal predictors of prostate cancer. Urol Int 79:13-18.
25. Steuber T, Helo P, Lilja H. (2007). Circulating biomarkers for prostate cancer. World J Urol 25:111-119
26. Tinzl M, Marberger M, Horvath S, Chypre C. (2004). DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 46:182-187
27. Vaananen RM, Rissanen M, Kauko O, Junnila S, Vaisanen V, Nurmi J, Alanen K, Nurmi M, Pettersson K. (2008). Quantitative real-time RT-PCR assay for PCA3. Clin Biochem 41:103-108
28. Van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. (2003). Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225 (Pubitemid 37267805)
29. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. (1991). Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51:3748-3752